Charles River and Wheeler Bio partner on therapeutic discovery
22 Feb 2024
Preview
Source: Pharmaceutical Technology
The integrated offering is aimed at simplifying the management of multiple vendor relationships, connecting preclinical work. Credit: fotohunter/Shutterstock.com.
Charles River Laboratories has entered a strategic partnership with Wheeler Bio to expedite the progression from therapeutic discovery to manufacturing for its clients.
The collaboration will offer a transition from preclinical activities to investigational new drug (IND) submission, facilitating entry to first-in-human clinical trials for early-stage biotech enterprises.
Charles River’s clients will gain access to Wheeler’s portable CMC platform.
To speed up therapeutic development, Charles River’s expertise in antibody discovery, analytics and safety will be merged with Wheeler’s platform.
The integrated offering simplifies the management of multiple vendor relationships, connecting preclinical work, clinical manufacturing and release evaluations.
See Also:Immunocore and BMS partner to investigate first-line treatment for melanoma
Preview
Source: Pharmaceutical Technology
United Therapeutics sues FDA over handling of Liquidia’s NDA
Preview
Source: Pharmaceutical Technology
Early integration of CMC development in the discovery phase allows therapeutic developers to work alongside experts, ensuring that phase-appropriate manufacturing and analytics are utilised.
Charles River corporate senior vice-president and chief scientific officer Julie Frearson stated: “We are thrilled to provide Charles River clients with access to Wheeler’s innovative portable CMC platform, which will optimise their workflows and ultimately bring new treatments to patients faster.”
The platform is a validation-ready manufacturing process that lowers technical and regulatory risk.
Wheeler manages it from its process development laboratories in Oklahoma City, US, which also has a current good manufacturing practice facility with on-site Charles River RightSource quality control testing facilities.
The organisation offers modular work packages to startup biotechs, facilitating a high-quality, agile and cost-effective path to clinical supply.
Wheeler Bio CEO and co-founder Jesse McCool stated: “Wheeler is excited to expand our relationship with Charles River and to link with their discovery organisation. By integrating discovery CRO [contract research organisation] and CDMO [contract development and manufacturing organisation] workflows, we can speed our clients’ path to first-in-human trials, thereby achieving clinical decisions faster.
“Our combined sales teams look forward to co-promoting these services for the benefit of our biotech partners and their pipelines towards clinical impact.”
For more details,please visit the original website
The content of the article does not represent any opinions of Synapse and its affiliated companies. If there is any copyright infringement or error, please contact us, and we will deal with it within 24 hours.
Organizations
Indications
Targets
-Drugs
-Hot reports
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Leverages most recent intelligence information, enabling fullest potential.